Pharming gives business update for the 2008 first quarter

In a quarterly business update, Pharming Group NV has confirmed that it plans to re-submit its application for the recombinant C1 inhibitor, Rhucin, to the European Medicines Agency with additional clinical data. In parallel, it will pursue registration for the product in markets outside the European Union.